These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Current state of treatment and prevention of gastroduodenal side effects of non-steroidal antirheumatic drugs]. Bolten W Leber Magen Darm; 1991 Sep; 21(5):193-4, 196. PubMed ID: 1758234 [TBL] [Abstract][Full Text] [Related]
4. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
5. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111 [TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update. Dajani EZ; Agrawal NM J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335 [TBL] [Abstract][Full Text] [Related]
7. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. Lanas A Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979 [TBL] [Abstract][Full Text] [Related]
8. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591 [TBL] [Abstract][Full Text] [Related]
9. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Goldstein JL; Huang B; Amer F; Christopoulos NG Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480 [TBL] [Abstract][Full Text] [Related]
10. NSAID-induced gastrointestinal damage. A critical review of prophylaxis and therapy. McCarthy DM J Clin Gastroenterol; 1990; 12 Suppl 2():S13-20. PubMed ID: 1978842 [TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. McCarthy DM Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039 [TBL] [Abstract][Full Text] [Related]
15. [Prevention and therapy of NSAID-induced ulcers: fact versus myth]. Fried M; Bertschinger P Schweiz Med Wochenschr; 1996 Sep; 126(37):1569-72. PubMed ID: 8927961 [TBL] [Abstract][Full Text] [Related]
17. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558 [TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori infection and the use of NSAIDs. Bazzoli F; De Luca L; Graham DY Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):775-85. PubMed ID: 11566040 [TBL] [Abstract][Full Text] [Related]
19. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422 [TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C; Pelosini I Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]